To see the other types of publications on this topic, follow the link: R-C cycle.
Journal articles on the topic 'R-C cycle'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'R-C cycle.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Tarrad, Ali H. "A Perspective Evolution Methodology of Energy Management in a Subcritical Regenerative Organic Rankine Cycles Operate at Two Temperature Levels." Athens Journal of Τechnology & Engineering 8, no. 1 (January 20, 2021): 9–26. http://dx.doi.org/10.30958/ajte.8-1-1.
Full textAbstract:
The waste energy recovery and management philosophy represent a great challenge for scientists. This article outlines a scheme to utilize two different source temperature levels in the range of (160–200) °C. Two regenerative organic Rankine cycles (RORC) were implemented to construct a compound regenerative organic Rankine cycle (CRORC) to improve the energy management of the sources. The method of energy management for these cycles was accomplished by extracting a certain amount of energy from the high-temperature cycle and rejecting it to the working fluid in an economizer at the low-temperature level. R-123 was circulated in the high-temperature cycle due to its high critical temperature at evaporation and condensation temperatures of 150 °C and 50 °C respectively. R-123, R-245fa, R-1233zd-E, and the hydrocarbon R-600a were used as working fluids for the low-temperature cycle at evaporation and condensation temperatures of 130 °C and 35 °C respectively. This technique showed that the first law of thermodynamics efficiency was augmented by (3–5)% for the low-temperature mini-cycle of the (CRORC). The energy consumption at the low-temperature cycle was also reduced by (3–5)%. The latter reduction range accounts for 2% for the total extracted energy for the independent system where both high-temperature and low-temperature cycles were utilized separately. The data showed that increasing the superheat degree from 10 °C to 20°C has enhanced the thermal efficiency of the compound (CRORC) system by (2–4)%. The (CRORC) system of R-123/R600a, R-123/R-123, and R-123/R-245fa fluid pairs exhibited higher thermal efficiency than that of R-123/R-1233zd-E pair by (4.5–6)%, (4–6)% and (3–4)% respectively. The net thermal efficiency of the compound (CRORC) system fell in the range (12–13)% and the low-temperature mini-cycle of the (CRORC) system had a range of (12–14)% for all of the examined operating conditions. Keywords: compound cycle, regenerative, energy management, energy recovery
2
Tarrad, Ali H. "A Waste Energy Recovery Management for Electricity Generation from Two Temperature Grades of Energy Sources in Subcritical Organic Rankine Systems." Athens Journal of Τechnology & Engineering 8, no. 3 (September 6, 2021): 217–36. http://dx.doi.org/10.30958/ajte.8-3-2.
Full textAbstract:
Waste energy represents one of the most critical issues for the economic utilization and management of energy in modern industrial fields. This article outlines a scheme to utilize two different source temperature levels within the envelope of higher than 200 °C zones. Two regenerative organic Rankine cycles (RORC) were implemented to construct a compound regenerative organic Rankine cycle (CRORC) to improve the energy management of the sources. These two mini-cycles were integrated throughout an intermediate economizer circuit to extract a certain amount of energy from the high-temperature level mini-cycle. R-123 was circulated in the high-temperature cycle due to its high critical temperature at evaporation and condensation temperatures of 160 °C and 50 °C, respectively. R-123, R-21, and hydrocarbon R-600 were used as working fluids for the low-temperature cycle at evaporation and condensation temperatures of 130 °C and 35 °C, respectively. The R-123 fluid in the high-temperature mini-cycle was superheated to 170-240 °C, whereas the fluid in the low-temperature level was superheated to 180 °C. The results showed that the independent system (IRORC) requires more energy recovery than the compound system by a maximum of 2% to achieve the same net power output. This corresponds to the enhancement of 2% for the system net thermal efficiency of the compound (CRORC) system compared to the independent (IRORC) one. The compound (CRORC) system revealed a net thermal efficiency in the range of 14% and 15.6% for the test conditions. The mini-cycle net thermal efficiency of the low-temperature in the compound system was enhanced by a range of 2.5-5% compared to that of the independent arrangement. R-123/R-123 and R-123/R-21 systems exhibited higher net thermal efficiencies than the R-123/R-600 one by 3% and 2%, respectively. Increasing the superheat degree of the high-temperature mini-cycle from 10 °C to 80 °C for the compound system has improved the thermal efficiency by 7.6-7.9% for the examined fluid pairs and operating conditions. Keywords: compound cycle, regenerative, energy management, energy recovery, organic fluids
3
Wu, Shung-Liang. "3·2 r+1 -Cycle Systems of K n − C n." Graphs and Combinatorics 18, no. 3 (October 1, 2002): 687–90. http://dx.doi.org/10.1007/s003730200052.
Full text
4
COLLIER-CARTAINO, CLAYTON, NATHAN GRABER, and TAO JIANG. "Linear Turán Numbers of Linear Cycles and Cycle-Complete Ramsey Numbers." Combinatorics, Probability and Computing 27, no. 3 (November 2, 2017): 358–86. http://dx.doi.org/10.1017/s0963548317000530.
Full textAbstract:
Anr-uniform hypergraph is called anr-graph. A hypergraph islinearif every two edges intersect in at most one vertex. Given a linearr-graphHand a positive integern, thelinear Turán numberexL(n,H) is the maximum number of edges in a linearr-graphGthat does not containHas a subgraph. For each ℓ ≥ 3, letCrℓdenote ther-uniform linear cycle of length ℓ, which is anr-graph with edgese1, . . .,eℓsuch that, for alli∈ [ℓ−1], |ei∩ei+1|=1, |eℓ∩e1|=1 andei∩ej= ∅ for all other pairs {i,j},i≠j. For allr≥ 3 and ℓ ≥ 3, we show that there exists a positive constantc=cr,ℓ, depending onlyrand ℓ, such that exL(n,Crℓ) ≤cn1+1/⌊ℓ/2⌋. This answers a question of Kostochka, Mubayi and Verstraëte [30]. For even ℓ, our result extends the result of Bondy and Simonovits [7] on the Turán numbers of even cycles to linear hypergraphs.Using our results on linear Turán numbers, we also obtain bounds on the cycle-complete hypergraph Ramsey numbers. We show that there are positive constantsa=am,randb=bm,r, depending only onmandr, such that\begin{equation} R(C^r_{2m}, K^r_t)\leq a \Bigl(\frac{t}{\ln t}\Bigr)^{{m}/{(m-1)}} \quad\text{and}\quad R(C^r_{2m+1}, K^r_t)\leq b t^{{m}/{(m-1)}}. \end{equation}
5
Crasmareanu, Mircea. "Gradient-type deformations of cycles in EPH geometries." Studia Universitatis Babes-Bolyai Matematica 65, no. 4 (November 26, 2020): 641–49. http://dx.doi.org/10.24193/subbmath.2020.4.10.
Full textAbstract:
"The aim of this paper is to study the cycles of EPH geometries through their omogeneous gradient-type deformations recently introduced by the author. A special topic is the orthogonality between a given cycle $C$ and its deformations as well as between $C$ and its rotated version $R(C)$."
6
Yang, Ru, and Pai-Lu Wang. "Experimental Study of a Forced Convection Solar Collector/Regenerator for Open-Cycle Absorption Cooling." Journal of Solar Energy Engineering 116, no. 4 (November 1, 1994): 194–99. http://dx.doi.org/10.1115/1.2930081.
Full textAbstract:
This paper presents an experimental study of the performance of a forced convection glazed solar collector/regenerator (C/R) operated under the meteorological conditions of Kaohsiung, Taiwan. The C/R is the key component of an open-cycle absorption solar cooling system because its performance directly indicates the system performance. The present results show that the counterflow case can improve the C/R efficiency when inlet solution concentration is low. The effects of individual parameter on the C/R performance are analyzed. Dimensionless heat and mass transfer coefficients are given.
7
Crowe, Adam J., and Bart M. Bartlett. "Influence of steric bulk on the oxidative stability of phenolate-based magnesium-ion battery electrolytes." Journal of Materials Chemistry A 4, no. 2 (2016): 368–71. http://dx.doi.org/10.1039/c5ta07479g.
Full textAbstract:
A compilation of electrolytes within the standard RPhOMgCl and AlCl3 in a THF electrolyte system with varying alkyl-based steric bulks about the phenol ring were prepared and cycled electrochemically. For R = 2,4,6-Me3, excellent cycling (>200 h cycle life at C/10 current) with Mo6S8 Cheverel is observed.
8
Johnsen, B. P., T. A. Cruse, R. A. Miller, and W. J. Brindley. "Compressive Fatigue of a Plasma Sprayed Zr02-8 wt%Y203 and Zr02-10wt%NiCrAlCoY TTBC." Journal of Engineering Materials and Technology 117, no. 3 (July 1, 1995): 305–10. http://dx.doi.org/10.1115/1.2804544.
Full textAbstract:
High cycle (>106 cycles) fatigue (HCF) behavior of thick thermal barrier coatings (TTBC’s) was examined for applied stresses near the compressive strength of the material. Test data were obtained on four coating systems: two base materials in the unsealed and CrO2 dip sealed conditions. Free standing tubular specimens were evaluated. The data show that compressive fatigue limits exist for the four coating systems at room temperature (RT) and sealing with CrO2 improves RT fatigue life. Test results also show the ratio of the peak cyclic stress, at 105 cycles, to ultimate compressive strength (UCS) of the Yttria Stabilized Zirconia (YSZ) tubular specimens approaches 0.90 at R = 0.6 (R = minimum/maximum compressive stress). Residual UCS increases were observed after fatigue run-outs at elevated temperatures (5 at 700°C and 1 at 400°C) for both YSZ and the cermet. Ratchetting with cyclic hardening was observed during fatigue with deformation occurring primarily in the initial portion of the high cycle fatigue life of the specimens.
9
Nový, František, Libor Trško, Robert Ulewicz, and Sylvia Dundeková. "Influence of Electrodeposited Coatings on Ultra-High-Cycle Fatigue Life of S235 Structural Steel." Materials Science Forum 818 (May 2015): 37–40. http://dx.doi.org/10.4028/www.scientific.net/msf.818.37.
Full textAbstract:
The article deals with experimental results of fatigue life of plain carbon steel electrodeposited with nickel, chromium and iron-zinc coatings in the ultra-high-cycle region of loading (N = 6×106 ÷ 1010 cycles) obtained at high-frequency fatigue testing (f ≈ 20 kHz, T = 20 ± 5 °C, R = -1). The results confirm continuous decrease of S-N curves after N = 107 cycles. Electrodeposited coatings caused decrease of the fatigue life in the low and high-cycle fatigue region. In the ultra-high cycle region the influence of electrodeposited coatings on fatigue properties is negligible. There was observed no significant influence of thickness of electrodeposited coatings on fatigue lifetime decrease.
10
Bermejo, I., I. García-Marco, and E. Reyes. "Graphs and complete intersection toric ideals." Journal of Algebra and Its Applications 14, no. 09 (July 10, 2015): 1540011. http://dx.doi.org/10.1142/s0219498815400113.
Full textAbstract:
Our purpose is to study the family of simple undirected graphs whose toric ideal is a complete intersection from both an algorithmic and a combinatorial point of view. We obtain a polynomial time algorithm that, given a graph G, checks whether its toric ideal PG is a complete intersection or not. Whenever PG is a complete intersection, the algorithm also returns a minimal set of generators of PG. Moreover, we prove that if G is a connected graph and PG is a complete intersection, then there exist two induced subgraphs R and C of G such that the vertex set V(G) of G is the disjoint union of V(R) and V(C), where R is a bipartite ring graph and C is either the empty graph, an odd primitive cycle, or consists of two odd primitive cycles properly connected. Finally, if R is 2-connected and C is connected, we list the families of graphs whose toric ideals are complete intersection.
11
Newman, Nicholas, and Vitaly Voloshin. "Colorings of (r, r)-Uniform, Complete, Circular, Mixed Hypergraphs." Mathematics 9, no. 8 (April 10, 2021): 828. http://dx.doi.org/10.3390/math9080828.
Full textAbstract:
In colorings of some block designs, the vertices of blocks can be thought of as hyperedges of a hypergraph H that can be placed on a circle and colored according to some rules that are related to colorings of circular mixed hypergraphs. A mixed hypergraph H is called circular if there exists a host cycle on the vertex set X such that every edge (C- or D-) induces a connected subgraph of this cycle. We propose an algorithm to color the (r,r)-uniform, complete, circular, mixed hypergraphs for all feasible values with no gaps. In doing so, we show χ(H)=2 and χ¯(H)=n−s or n−s−1 where s is the sieve number.
12
Nyman, D. W., R. Mena, R. Robles, M. Auerbach, and L. Pandit. "A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, cytoxan, and rituxan (PCR) in the treatment of previously untreated or treated stage III or IV, low-grade CLL." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 6606. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.6606.
Full textAbstract:
6606 Background: The decision to treat indolent CLL is often based on progressive bulky disease, worsening symptoms, and increasing hematological derangement. When treatment is indicated, these lymphoproliferative disorders are sensitive to combination immunochemotherapies utilizing pentostatin (P), a purine analog, cyclophosphamide (C), a DNA alkylator, and rituximab (R), a potent anti-CD20 monoclonal antibody. P+C+R represents a promising new approach in the treatment of patients with low grade CLL. Methods: Eligibility criteria allow previously treated and treatment-naïve patients diagnosed with low-grade stage III/IV CLL (modified Rai classification). Treatment consisted of intravenous infusions of P (4 mg/m2), C (600 mg/m2), and R (375 mg/m2) on day 1 of a 21-day cycle for a total of 8 cycles. Clinical evaluation (including CT scan) was performed after cycles 2, 4, 6, and 8. Patients were stratified by disease and by prior treatment status. Results: The intent-to-treat (ITT) population consisted of 41 CLL patients (median age 64, range 36–85) who received a total of 207 cycles (median 4 per patient). ECOG status at enrollment was 0 (66%), 1 (27%) and 2 (7%). The overall response rate was 61% (CR 13%, PR 48%). One grade 4 neutropenia was documented. Four deaths have been recorded. An 81 YO patient was hospitalized 8 days after cycle 1; death, due to sepsis, occurred 22 days later. The death of an 83 YO was reported 10 days after cycle 2 as a result of an acute MI. An 83 YO patient, who developed gastroenteritis, was hospitalized 10 days after cycle 2. This progressed to dehydration and atrial flutter. Death came as a result of pulmonary edema and ASHD. An 82 YO man was hospitalized 4 days after completing cycle 2. He presented with extreme dyspnea but cause of death was CLL. Conclusions: This immunochemotherapeutic regimen is active in Grade III/IV CLL and the incidence of significant toxicities was low with deaths occurring only in elderly (>80 YO) patients. Updated results of this trial will be presented at the ASCO meeting. No significant financial relationships to disclose.
13
Stachel, Aleksander A., and Sławomir Wiśniewski. "Influence of the type of working fluid in the lower cycle and superheated steam parameters in the upper cycle on effectiveness of operation of binary power plant." Archives of Thermodynamics 36, no. 1 (March 1, 2015): 111–23. http://dx.doi.org/10.1515/aoter-2015-0008.
Full textAbstract:
Abstract In the paper presented have been the results of the analysis of effectiveness of operation of binary power plant consisting of combined two Clausius-Rankine cycles, namely the binary cycle with water as a working fluid in the upper cycle and organic substance as a working fluid in the lower cycle, as well as a single fluid component power plant operating also in line with the C-R cycle for superheated steam, with water as a working fluid. The influence of the parameters of superheated steam in the upper cycle has been assessed as well as the type of working fluid in the lower cycle. The results of calculations have been referred to the single-cycle classical steam power plant operating at the same parameters of superheated steam and the same mass flow rate of water circulating in both cycles. On the basis of accomplished analysis it has been shown that the binary power plant shows a greater power with respect to the reference power plant.
14
Wu, Shyi-Kaan, and Yi-Ching Chang. "Thermal Cycling Effect on Transformation Temperatures of Different Transformation Sequences in TiNi-Based Shape Memory Alloys." Materials 12, no. 16 (August 7, 2019): 2512. http://dx.doi.org/10.3390/ma12162512.
Full textAbstract:
In TiNi-based shape memory alloys (SMAs), the effects of thermal cycling on the transformation peak temperatures of B2 ↔ B19′, B2 ↔ R, B2 ↔ B19, B2 ↔ R ↔ B19′, and B2 ↔ B19 ↔ B19′ one-stage and two-stage transformations have been investigated and compared. Experimental results of the differential scanning calorimeter and hardness tests indicate that the alloy’s intrinsic hardness and the shear strain, s, associated with martensitic transformation, are two important factors, due to their relation to the ease of introducing dislocations during cycling. The temperature decrease by cycling for one-stage transformation was in the order of B2 ↔ B19′ > B2 ↔ B19 > B2 ↔ R according to the orders of magnitude of their s values. This phenomenon also affected the suppression of B19 ↔ B19′ and R ↔ B19′ transformation peak temperatures in two-stage transformation. Both Ti50Ni48Fe2 and Ti48.7Ni51.3 SMAs aged at 450 °C for 4 h exhibited B2 ↔ R ↔ B19′ transformation, but the hardness of the latter was much higher than that of the former due to the precipitation hardening of the Ti3Ni4 precipitates. This causesd the decrease of the R ↔ B19′ transformation peak temperature in the Ti50Ni48Fe2 SMA to be much higher than that in Ti48.7Ni51.3 SMAs aged at 450 °C for 4 h, which directly affected the sequential B2 ↔ R transformation of Ti50Ni48Fe2 SMA in the next thermal cycle and decreased this transformation peak temperature. The Ti48Ni52 SMA aged at 600 °C for 150 h underwent B2 ↔ B19′ transformation and then B2 → R → B19′/B19′ → B2 transformation as the cycle number increased, in which the B2 ↔ R transformation peak temperature raised slightly by cycling. This characteristic is uncommon and may have resulted from the strain field around the thermal-cycled dislocations favoring the formation of the R-phase.
15
Istiqomah, Meighina Atika, Poppy Anjelisa Zaitun Hasibuan, Arif Nuryawan, Sumaiyah Sumaiyah, Etti Sartina Siregar, and Mohammad Basyuni. "The Anticancer Compound Dolichol from Ceriops tagal and Rhizophora mucronata Leaves Regulates Gene Expressions in WiDr Colon Cancer." Sains Malaysiana 50, no. 1 (January 31, 2021): 181–89. http://dx.doi.org/10.17576/jsm-2021-5001-18.
Full textAbstract:
Mangrove plants produce polyisoprenoid alcohol. The polyisoprenoid consists of polyprenol and dolichol, which in pharmacological activity act as anticancer agents. The major polyisoprenoid compound of mangrove plants Ceriops tagal and Rhizophora mucronata was reported as dolichol. The present study was conducted to examine the anticancer effects of dolichol from C. tagal and R. mucronata leaves on WiDr cells and cell cycle-related cancer for 24 h and to evaluate the regulation of five genes, p53, EGFR, PI3K, Akt, and mTOR. The inhibited cell cycle was analysed by flow cytometry and the gene expression of p53, EGFR, PI3K, Akt, and mTOR was determined using reverse transcription-polymerase chain reaction (RT-PCR) method. Dolichol from C. tagal was more effective than that from R. mucronata,where it worked on the G0/G1 cycle for 87.94% and 82.36%, respectively, and regulated positive control 5-FU on the G0/G1 cycle (88.12%), S (9.52%) and G2-M (6.42%). The upregulation (p53) and downregulation (EGFR)contributed to the contracting cell cycle of colon cancer cells (WiDr) in PI3K, Akt and mTOR genes. To summarise, the current study suggests significant pharmacological properties of dolichols in C. tagal and R. mucronata leaves, which worked explicitly in the G0/G1 phase.
16
Yamamoto, N., Y. Yamada, H. Nokihara, Y. Goto, M. Tanioka, K. Yamada, F. Koizumi, N. Koyama, and T. Tamura. "Plasma biomarkers predictive for disease control duration in the phase I study of E7080, a multitarget kinase inhibitor." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e14524-e14524. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e14524.
Full textAbstract:
e14524 Background: E7080 is an oral multi-targeted kinase inhibitor of VEGFRs, PDGFRs, FGFRs and c-kit. In the phase I study for advanced solid tumors, E7080 was repeated every 3 weeks (twice daily by 2 wks-on/ 1 wk-off). The toxicities were manageable and the preliminary antitumor activity including one partial response was observed at doses up to MTD [ASCO 2008; abstract 3527]. This study was conducted to evaluate whether the change of plasma biomarkers in the E7080 phase I study could predict the antitumor activity or the disease control duration. Methods: The treatment duration was determined as a period from the first dosing to treatment failure. Plasma angiogenic proteins and circulating endothelial cells (CEC)/ progenitor cells (CEP) were measured in blood samples collected on Days 1 (pre-dose), 8 and 15 of Cycles 1 and 2. CEC and CEP population with (+) or (-) c-kit expression were analyzed by FACS. Correlation was determined by Spearman's rank correlation coefficient (r) and test for non-correlation (p). Results: 19 (76%) out of 25 evaluable patients had PR/SD including 6 (24%) patients with the treatment duration of ≥180 days. VEGF increase and sVEGFR1 and -R2 decreases in plasma were seen with the increased dose of E7080. But these changes had no correlations with disease control. E7080 decreased c-kit(+) CEC and CEP, but not c-kit(-) population. Importantly, patients showing the decrease of c-kit(+) CEC in Cycle 1 had received E7080 treatment for significantly longer duration (r=-0.468, p=0.018). The decrease of c- kit(+) CEC diminished during treatment-off for final 7 days in Cycle 1 and repeatedly decreased in Cycle 2 treatment. The decrease of c- kit(+) ratio in CEP correlated with the increase of plasma SCF (r=-0.457, p=0.021) and SDF1 (r=-0.466, p=0.018), but not with VEGF or thrombopoietin. Conclusions: The change of c-kit(+) CEC correlated with the disease control duration in the phase I study of E7080. SCF and SDF1 may play a role in c-kit(+) CEP accumulation. C-kit(+)-selective changes of CEC could be a candidate biomarker to predict the disease control duration in anti-angiogenic therapy of E7080. [Table: see text]
17
Matasar, Matthew J., Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yanez, Katya Sapunarova, et al. "Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 7510. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7510.
Full textAbstract:
7510 Background: Rituximab (R) monotherapy is an approved treatment for patients (pts) with relapsed indolent NHL (iNHL) who have a prolonged progression-free and treatment-free interval after last R-based therapy or who are unwilling/unfit to receive chemotherapy. Copanlisib (C) is a PI3K inhibitor approved as monotherapy in pts with relapsed FL who have progressed after ≥2 systemic therapies. The recent Phase III CHRONOS-3 study in pts with relapsed iNHL treated with C+R vs placebo (P)+R (NCT02367040) met its primary endpoint with a significant 48% reduction in the risk of disease progression or death (Matasar et al. AACR 2021). We report here a pre-planned subset analysis in pts with relapsed FL or MZL. Methods: Pts with relapsed iNHL who were progression- and treatment-free for ≥12 months (mo) after last R-based therapy or ≥6 mo if unwilling/unfit to receive chemotherapy were randomized 2:1 to receive C+R or P+R. C 60 mg/P was given i.v. on days 1, 8, and 15 (28-day cycle); R 375 mg/m2 was given i.v. on days 1, 8, 15, and 22 of cycle 1 and on day 1 of cycles 3, 5, 7, and 9. Primary endpoint was centrally assessed progression-free survival (PFS) by Cheson 2014 criteria. Secondary endpoints included objective response rate (ORR), duration of response (DoR), complete response rate (CRR), time to progression (TTP), and treatment-emergent adverse events (TEAEs). All randomized pts were assessed for efficacy; pts were assessed for safety if they received ≥1 dose of C/P or R. The data cut-off date was August 31, 2020. Results: From a total dataset of 458 iNHL pts, 250 pts with FL/MZL (184 FL/66 MZL) were randomized to C+R and 120 (91 FL/29 MZL) to P+R. Median age was 62 years (range 28-91) and the arms were well balanced. With a median follow-up of 18.5 mo, C+R significantly reduced the risk of disease progression/death vs P+R (HR = 0.55 [95% CI 0.40, 0.76]; 1-sided p = 0.0001); median PFS was 22.2 mo (95% CI 19.1, 33.1) vs 15.4 mo (95% CI 11.0, 19.2), respectively. Median TTP was 27.5 mo for C+R vs 15.4 mo for P+R (HR = 0.500; 1-sided p = 0.00001). ORRs were 82.4% (CRR 37.6%) for C+R and 50.8% (CRR 18.3%) for P+R; median DoR was 23.9 mo vs 17.9 mo, respectively. Most common TEAEs (all grades [G]/G3+) in pts with FL/MZL receiving C+R (n = 249) were hyperglycemia (72.7%/59.0%), hypertension (53.8%/43.0% [all G3]), and diarrhea (35.3%/5.6% [all G3]). For pts receiving P+R (n = 116), the most common TEAEs were hyperglycemia (23.3%/7.8% [all G3]), hypertension (19.8%/8.6% [all G3]), neutropenia (18.1%/13.8%), and upper respiratory tract infection (18.1%/0%). Conclusions: C+R demonstrated superior efficacy vs P+R in pts with relapsed FL/MZL and had a manageable safety profile, consistent with C and R as monotherapy. Copanlisib is the first PI3K inhibitor to be safely combined with R in relapsed FL/MZL, representing a potential new therapeutic option. Clinical trial information: NCT02367040.
18
GILARDI, Giovanna, Massimo PUGLIESE, Maria Lodovica GULLINO, and Angelo GARIBALDI. "Evaluation of different carbon sources for anaerobic soil disinfestation against Rhizoctonia solani on lettuce in controlled production systems." Phytopathologia Mediterranea 59, no. 1 (March 14, 2020): 77–96. http://dx.doi.org/10.36253/phyto-10911.
Full textAbstract:
Effects of anaerobic soil disinfestation (ASD) on Rhizoctonia solani basal rot of lettuce were assessed considering: two soil types; different C-sources; different temperature regimes; two treatment durations; and two lettuce crop cycles, in the presence of a high disease incidence from artificial infestation with the pathogen. C-source, temperature, and incubation period, and their interaction, affected the efficacy of the ASD treatment for the lettuce–R. solani pathosystem, with differences depending on the soil type. Brassica carinata pellets, used as a C-source, reduced incidence of Rhizoctonia basal rot in the first crop cycle by 50 to 69% in a peat soil after 3 weeks of treatment at 21°C, and by 52 to 60% after 3 weeks of treatment at 26 or 31°C, compared to the inoculated and untreated experimental controls without anaerobic conditions. The best disease reduction was provided by B. carinata pellets applied, under anaerobic conditions, to peat soil (79% efficacy) and a sandy loam soil (100% efficacy) kept at 31°C for 6 weeks. Generally, ASD based on B. carinata pellets provided greater disease reduction in the first crop cycle than the second, with the only exception being for results achieved in both soils incubated for 6 weeks at 21, 26 and 31°C. Wild rocket used as a C-source provided the greatest disease reduction (78–83%) on plants grown in peat soil at the first crop cycle after 6 weeks of the ASD treatment at 31°C, while wild rocket provided disease reduction of 29 and 50% when mixed with the sandy-loam soil under the same conditions for 6 weeks. The efficacy of the ASD treatment with compost was improved in the second crop cycle, compared to the first, resulting in the greatest disease reduction (52 and 66% efficacy) reached in the sandy-loam soil incubated for 3 weeks at 21°C, and 63% efficacy in peat soil previously treated for 6 weeks at 26 and 31°C. However, slight reductions in lettuce plant development was generally evident in the first crop cycle, which could be due to differences in efficacy of the tested ASD treatments and to phytotoxicity. The greatest yield from sandy loam soil was obtained for the B. carinata pellets and wild rocket at 26 and 31°C in the second cultivation cycle. Partial efficacy of ASD does not justify the adoption of this method against R. solani on lettuce under intensive crop systems. However, ASD based on Brassicaceae and compost as carbon source applied in a sandy-loam soil may be valuable for reducing R. solani incidence, at lower temperatures than those required for soil solarisation or biosolarisation.
19
Huang, Jane E., Lowell Hart, Jonathon Polikoff, Virginia Langmuir, Fan Zhang, and Louis Fehrenbacher. "Rituximab Plus CHOP Followed by Maintenance Rituximab as Initial Therapy for Advanced Stage Indolent Non-Hodgkin’s Lymphoma (NHL); Initial Results of Induction Therapy in a Phase II Study." Blood 104, no. 11 (November 16, 2004): 4615. http://dx.doi.org/10.1182/blood.v104.11.4615.4615.
Full textAbstract:
Abstract Background: This study was designed to investigate the activity and safety of rituximab (Rituxan®, R) plus CHOP induction therapy followed by maintenance R in patients with previously untreated advanced stage indolent NHL. The initial results of R-CHOP induction treatment are reported here. Methods: 102 patients with Ann Arbor Stage III or IV indolent NHL (follicle center/follicular grade I/II or nodal marginal zone B-cell by REAL; Type B or C by IWF) were enrolled into this open-label, multi-center, community-based, Phase II, single-arm trial. Patients received 6 cycles of standard R-CHOP induction therapy (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, doxorubicin 50 mg/m2 all IV on Day 1; prednisone 100 mg/day Days 1–5). R 375 mg/m2 was given on Day 1 of each cycle except for cycle 1, when it was administered 2–3 days prior to CHOP chemotherapy. Subjects with an ongoing response (CR/CRu or PR) after induction receive maintenance R (4 weekly infusions) within 28 days after the completion of induction and repeated every 6 months for 2 years for a total of 16 maintenance R doses. The primary endpoints were CR/CRu after 6 cycles of induction and the incidence of R infusion-related toxicity during induction and maintenance therapy. Secondary endpoints included overall response rates (ORR), infusion times, serious adverse events (SAE) in induction and maintenance, and rituximab pharmacokinetics in maintenance therapy. Results: Baseline characteristics were: median age 57y (33.3% ≥60y); 40.2% female; ECOG performance status 0: 70.6%; Ann Arbor stage III: 28.4% and IV: 71.6%. Serum β2-microglobulin and LDH at baseline were above normal in 66.3% and 20.6%, respectively. CR/CRu at the end of induction in 102 patients was 51.0% (ORR 86.3%). 1% had progressive disease (PD) during induction. 2 subjects died during the induction period, both due to SAEs (probable pulmonary embolus, acute respiratory distress). SAEs occurred in 22.5% of subjects during induction with the most common event being febrile neutropenia (7.8%). Grade 3–4 R infusion-related toxicity occurred in 4.9% of patients in cycle 1; this decreased to 1% by cycle 2 of induction. Two subjects discontinued R for infusion-related toxicity. 44% of patients were able to receive their R dose within 3 hrs at cycle 2 and 69.2% of patients at cycle 6. Conclusion: Patients with advanced stage indolent NHL treated in the community setting with R-CHOP induction tolerate therapy well and have an excellent response rate. The outcomes of maintenance therapy and rituximab pharmacokinetics in maintenance await further follow-up.
20
Hue, Olivier. "Prediction of Drafted-Triathlon Race Time From Submaximal Laboratory Testing in Elite Triathletes." Canadian Journal of Applied Physiology 28, no. 4 (August 1, 2003): 547–60. http://dx.doi.org/10.1139/h03-042.
Full textAbstract:
Purpose and methods: To determine which physiological variables accurately predict the race time of an Olympic-distance International Triathlon undertaken in drafted conditions, 8 elite triathletes underwent both maximal and submaximal laboratory and field physiological testing: a 400-m maximal swim test; an incremental treadmill test; an incremental cycling test; 30 min of cycling followed by 20 min of running (C-R); and 20 min of control running (R) at the exact same speed variations as in running in C-R. Blood samples were drawn to measure venous lactate concentration after the 400-m swim and the cycle and run segments of C-R. During the maximal cycling and running exercises, data were collected using an automated breath-by-breath system. Results: The only parameters correlated with the overall drafted-triathlon time were lactate concentration noted at the end of the cycle segment (r = 0.83, p < 0. 05) and the distance covered during the running part of the submaximal C-R test (r = -0.92, p < 0.01). Stepwise multiple regression analysis revealed a highly significant (r = 0.96, p < 0.02) relationship between predicted race time (from laboratory measures) and actual race time, using the following calculation: Predicted Triathlon Time (s) = -1.128 (distance covered during R of C-R [m]) + 38.8 ([lactate] at the end of C in C-R) + 13,338. The high R2 value of 0.93 indicated that, taken together, these two laboratory measures could account for 93% of the variance in race times during a drafted triathlon. Conclusion: Complementing previous studies, this study demonstrates that different parameters seem to be reliable for predicting performance in drafted vs. nondrafted Olympic-triathlon races. It also demonstrates that, for elite triathletes competing in a drafted Olympic-distance triathlon, performance is accurately predicted from the results of submaximal laboratory measures. Key words: swimming, cycling, running, lactate, oxygen uptake
21
Purnama, Adam, Lilis Imamah Ichdayati, and Rahmi Purnomowati. "ANALISIS FAKTOR-FAKTOR YANG MEMPENGARUHI EFISIENSI PRODUKSI BENIH IKAN PATIN (STUDI KASUS PANDAWA LIMA FISHERIES FARM BOGOR)." AGRIBUSINESS JOURNAL 11, no. 1 (July 15, 2019): 81–90. http://dx.doi.org/10.15408/aj.v11i1.11836.
Full textAbstract:
The objectives of this research are; (1) to determine the factors effecting seed production of catfish in the Pandawa Lima Fisheries Farm Bogor, (2) to determine the elasticity of seed production of catfish in the Pandawa Lima Fisheries Farm Bogor, and (3) to determine the level of technical efficiency on hatchery operations of catfish in Pandawa Lima Fisheries Farm Bogor. The R/C analysis was employed to analyze income of catfish seed production for 30 cycles of production. Results showed that farm income is positive with a value of Rp 851,343.75 per cycle. The R/C value was 1.12 indicated that catfish hatcheries in Pandawa Lima Fisheries Farm is considered advantageous to cultivate.
22
Ji, In Hwan, Sauvik Chowdhury, Blake Powell, Kiran Chatty, Sujit Banerjee, and Kevin Matocha. "Comparative Study on the Repetitive Unclamped-Inductive-Switching Capability(R-UIS) of 1200V 160mOhm SiC Planar Gate MOSFETs." Materials Science Forum 963 (July 2019): 792–96. http://dx.doi.org/10.4028/www.scientific.net/msf.963.792.
Full textAbstract:
This paper presents the comparative study on the repetitive unclamped inductive load switching capabilites in comercialized 1200V, 160mΩ rated SiC MOSFETs. Recently released Littelfuse-Monolith 1200V 160 mOhm design (LSIC1MO120E0160) manufactured through 150mm high volume CMOS compatible process demonstrated excellent R-UIS capabilities: no parametric shift on key electrical performances such as on-resistance, threshold voltage, breakdown voltage and drain leakage current after 100000 cycles of R-UIS stress. Both Competitor A and B design with planar gate showed R-UIS capabilities. All critical parameters were within the datasheet specification after R-UIS test. Competitor A design was equivalent to LSIC1MO120E0160. Competitor B design showed the drain leakage increase after 2000 cycle of R-UIS stress. Competitor C design with trench gate did not exhibit any R-UIS capabilities.
23
Jiang, Tao, and Liana Yepremyan. "Supersaturation of even linear cycles in linear hypergraphs." Combinatorics, Probability and Computing 29, no. 5 (June 23, 2020): 698–721. http://dx.doi.org/10.1017/s0963548320000206.
Full textAbstract:
AbstractA classical result of Erdős and, independently, of Bondy and Simonovits [3] says that the maximum number of edges in an n-vertex graph not containing C2k, the cycle of length 2k, is O(n1+1/k). Simonovits established a corresponding supersaturation result for C2k’s, showing that there exist positive constants C,c depending only on k such that every n-vertex graph G with e(G)⩾ Cn1+1/k contains at least c(e(G)/v(G))2k copies of C2k, this number of copies tightly achieved by the random graph (up to a multiplicative constant).In this paper we extend Simonovits' result to a supersaturation result of r-uniform linear cycles of even length in r-uniform linear hypergraphs. Our proof is self-contained and includes the r = 2 case. As an auxiliary tool, we develop a reduction lemma from general host graphs to almost-regular host graphs that can be used for other supersaturation problems, and may therefore be of independent interest.
24
Tam, Constantine S., John Francis Seymour, Michael Brown, Philip Campbell, John D. Scarlett, Craig Underhill, David Ritchie, Rodney Bond, and Andrew Grigg. "A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R)." Blood 104, no. 11 (November 16, 2004): 3313. http://dx.doi.org/10.1182/blood.v104.11.3313.3313.
Full textAbstract:
Abstract The monoclonal anti-CD20 antibody R improves response rates and survival when added to FC in patients with CLL (Keating Proc ASCO 2004, abstr #6565), but the associated B-cell depletion may increase the infectious risk associated with FC therapy. We therefore compared infectious episodes both during and in the 12 months following therapy in two cohorts of patients treated with FC (F 25mg/m2x3, C 250mg/m2x3 q28 days; n=63) alone or with R (FCR; FC+R 375mg/m2 day 1; n = 91) for indolent lymphoid malignancies. Patients received FC from 10/96 to 12/00 and FCR from 12/00 to 8/03. Both cohorts had similar baseline characteristics including history of infections, neutrophil counts, and Ig levels and were mainly elderly (median age 60 years, range 30–89) with heavily pretreated disease (median number of previous therapies 2, range 1–10) and both received a median of 4 cycles of therapy without routine antibiotic prophylaxis or growth-factors; CLL or follicular lymphomas constituted over two-thirds of group. In comparison to FC, infectious episodes were not significantly increased for FCR either during therapy (FC 15%/cycle vs FCR 20%/cycle, p=0.17) or in the first 12 months of remission (1 infection per 13 patient-months [PM] for both cohorts). There was a trend to increased late neutropenia in the FCR cohort (14% vs 31% at 3 months; P = 0.15). Grade 3+ infections were similar both during therapy (FC 8%/cycle vs FCR 9%/cycle) and in the first 12 months of remission (FC 1 per 84 PM vs FCR 1 per 35PM, p=0.16), as were rates of herpes virus infections (FC vs FCR: during therapy 1% vs 2%/cycle; during follow-up 1 per 48 vs 1 per 94 PM). We conclude that the addition of R to FC does not result in increased early or late infectious risk above that of FC alone.
25
Extermann, Martine, Christine Marie Walko, Asmita Mishra, Kerry Thomas, Biwei Cao, Hye Sook Chon, Mihaela C. Cristea, et al. "Is age-related worsening in ovarian cancer prognosis linked to changes in body composition and pharmacokinetics?" Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e17553-e17553. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e17553.
Full textAbstract:
e17553 Background: The prognosis of ovarian cancer worsens markedly with age. Yet few data are available to explain this phenomenon. Two hypotheses can be made. Changes in pharmacokinetics and treatment tolerance limit the dosing of chemotherapy. And/or changes in tumor and host-tumor biology limit treatment efficacy. Methods: We conducted a prospective cohort study of women with stage III/IV high-grade serous ovarian cancers treated with neoadjuvant intravenous carboplatin(C) AUC 5 every 3 weeks and paclitaxel(P) dosed either weekly at 80 mg/m2 or every 3 weeks at 175 mg/m2. Body composition was assessed using baseline CT scans at the L3 level. Total muscle mass, total fat mass, skeletal muscle index (SMI) and fat index were computed. Plasma concentrations were collected at pre-established time points for both C1D1 of C and P and concentration-time data was analyzed by non-compartmental methods. Area under the curve (AUC)0-INF, volume of distribution(Vd), clearance (Cl), half-life, and mean residence time were calculated. Free C concentrations were determined in plasma ultrafiltrate and assayed, along with P plasma concentrations, by liquid chromatography-tandem mass spectrometry. Toxicity was assessed as first cycle nadir ANC and G4 hematologic(H) or grade 3-4 non-hematologic(NH) toxicity by CTCAE 4.0 criteria over a 3 cycles follow-up. The correlation between continuous measures was assessed by Spearman correlation coefficient, and the association with toxicity was evaluated by Wilcoxon rank sum test. Results: Seventeen patients, ages 38 to 86 (median 61) were eligible. All patients but one received 3 cycles of chemotherapy and median dose intensity was 100% (range 33.3-100%). Mean 1st cycle nadir ANC was 1.29 (range 0.06-9.0). 10/17 (59%) patients experienced G4 H and/or G3-4 NH toxicity. SMI was associated with C AUC (r -0.50, p < 0.05), and both total muscle (r = 0.61) and total fat (r = 0.53) were associated with C Vd. We did not find a correlation of P pharmacokinetics with body composition. A lower SMI was associated with 1st cycle G4H toxicity (p = 0.02), while C AUC had a borderline trend only (p = 0.15). Age was associated with a lower Vd (r -0.63, p = 0.009) and Cl (r -0.67, p = 0.004) of C. There was no significant age trend in the body composition parameters. Conclusions: Neoadjuvant treatment delivery was high in an academic setting. Toxicity appeared driven by low skeletal muscle index, in part via affecting carboplatin pharmacokinetics, and showed no significant age trend. The explanation for age-related changes in prognosis is more likely to lay with changes in tumor and host-tumor biology, which are being analyzed.
26
Abali, Huseyin, Suayib Yalcin, Huseyin Cem Onal, Faysal Dane, Berna Oksuzoglu, Nuriye Ozdemir, Huseyin Mertsoylu, et al. "A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastro-esophageal junction cancer (TOXAG study)." Journal of Clinical Oncology 34, no. 4_suppl (February 1, 2016): TPS182. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.tps182.
Full textAbstract:
TPS182 Background: Trastuzumab in combination with chemotherapy has been shown to prolong survival of HER2+ esophago-gastric cancer patients. The primary aim of our study was to evaluate safety and tolerability of trastuzumab (T) in combination with oxaliplatine (O), capecitabine (C) and radiation (R) therapy in the adjuvant setting in curatively resected esophago-gastric cancer patients. Methods: Forty patients with IB or higher stages was planned to be recruited and here we report the interim analyses on 22. We would consider the study positive if at least 64.4% of patients could tolerate the therapy. Eligible patients received T 8 mg/kg intravenously (iv) on Day 1 of cycle 1 and 6 mg/kg iv on day 1 of every following 3-weekly cycle for 1 year as 17 cycles, with O 100 mg/m2 iv on Day 1 of cycles 1-3 and C 850 mg/m2 orally twice daily on days 1-14 of cycles 1-3 and on 5 days per week during chemo-radiotherapy. R was given at a total dose of 45 Gy divided into 25 doses on 5 treatment days per week for 5 weeks starting from the 1st day of cycle 4. Results The median age was 57.5 years (Min-Max: 35-74). Of 22 patients; 15 were male (68.2%), 21 (95.5%) had an ECOG PS score ≤ 1, 21 (95.5%) had D2 lymph node resection. There were 11 serious adverse events. Two patients died on therapy; 1 secondary to pulmonary thrombo-emboli, and the other had to cerebral ischemia (thought to be due to Behçet’s disease), and 7 died of progression. There were 6 dose reductions (1 for T, 2 for O and 3 for C), T was stopped in 1 patient, C was interrupted 8 times (mostly during radiotherapy). Patients who have completed 3 cycles of O, C, T and 4th and 5th cycles of chemo-radiation therapy with C and T were defined as tolerable. Out of 22 patients, 19 (86.4%) were tolerable (Chi Square test: p = 0.0623). Median survival time for interim analysis patients (n = 22) was 22 months (95% CI: 11-23 months). Conclusion T in combination with O, C and chemo-radiation with C and T was tolerable with the tolerability rate of 86.4%, in curatively resected HER2 + esophago-gastric cancer adjuvant treatment. Clinical trial information: NCT01748773.
27
Dunleavy, Kieron, Richard Little, Juan Gea-Banacloche, Nicole Grant, Seth Steinberg, Robert Yarchoan, Stefania Pittaluga, Elaine Jaffe, John Janik, and Wyndham H. Wilson. "Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL)." Blood 104, no. 11 (November 16, 2004): 3111. http://dx.doi.org/10.1182/blood.v104.11.3111.3111.
Full textAbstract:
Abstract In ARL, rituximab may slightly improve CHOP response but is associated with greater toxicity (Proc Am Soc Hem102:1488, 2003). We hypothesized that the addition of rituximab to DA-EPOCH may increase fractional tumor cell kill and allow fewer treatment cycles and lower immune suppression. Patients received DA-EPOCH-R (E=etoposide 50 mg/m2/d, O=vincristine 0.4 mg/m2/d and H=doxorubicin 10 mg/m2/d all CIV d 1–4 (96 hours); C=cyclophosphamide 750 mg/m2 IV d5; P=prednisone 60 mg/m2 PO qd d1–5 and R=rituximab 375 mg/m2 IV d1 and 5) with G-CSF. Prophylactic IT MTX x 6 was administered. HAART was discontinued before and recommenced after DA-EPOCH-R. Unlike our previous study of DA-EPOCH in ARL (BLOOD101:4653, 2003) where the dose of C was lower and based on CD4 cell count, all patients on this study received full dose C on cycle 1 with subsequent reduction if the ANC nadir was < 500/mm3 for ≥ 2 days. Patients received 1 cycle beyond CR, based on CT and PET, for a minimum of 3 cycles. Characteristics of 21 patients include median (range) age 39 (9–61) years; IPI 3 (0–4); ECOG PS 2 (1–4); CD4 212 (0–674) cells/mm3 and HIV viral load 53100 (0– 286472) RNA copies/mL. Additionally, male sex 17 (81%); LDH> nl 15 (71); stage IV 15 (71%) and histology with diffuse large B-cell 9 (90%) and Burkitt’s lymphoma 2 (10%). The 18 patients who completed treatment (2 TE; 1 NE) received a median (range) of 3 (3–5) cycles. Responses are CR/CRu 15 (83%); PR 1 (6%) and NR 2 (11%). At 19 mos median follow-up, overall PFS and OS are both 77%, and both 90% in patients with CD4 > 100 cells/mm3. Treatment outcome of DA-EPOCH-R is similar to DA-EPOCH (CR 74% and PFS 73% at 53 months) but with significantly shorter treatment (median cycles 3 vs. 6). Toxicity on 57 cycles include ANC < 500/mm3 on 27 (47%); platelets < 50,000/mm3 on 15 (26%) and; fever/neutropenia on 20 (35%) cycles. DA-EPOCH-R produced a median (range) CD4 cell decrement of 64 (−541 to + 239) cells/mm3 compared to 189 (−973 to +19) with DA-EPOCH. Hematological toxicity is higher with DA-EPOCH-R compared to DA-EPOCH with ANC < 500/mm3 47% vs 30% and fever/neutropenia 35% vs. 13%, respectively, likely due to higher C dose intensity and/or rituximab. Other toxicities are similar. Abbreviated DA-EPOCH-R is equivalent to DA-EPOCH x 6 and appears to produce less CD4 cell loss. Accrual continues. Figure Figure
28
Gu, Yu Li, Yu Huai He, Chang Kui Liu, and Chun Hu Tao. "Fatigue Deformation Behavior of FGH96 Superalloy under Low Cycle Fatigue Loading." Advanced Materials Research 641-642 (January 2013): 418–22. http://dx.doi.org/10.4028/www.scientific.net/amr.641-642.418.
Full textAbstract:
Low cycle fatigue failure tests of the powder metallurgical nickel based superalloy FGH96 at 550°C and 720°C were carried out under total strain-controlled mode (R=-1). The fatigue failure behaviors were investigated by analyzing cyclic stress response and observing microstructure after fatigue through scanning electron microscopy (SEM) and electron backscatter diffraction (EBSD). The results show that FGH96 superalloy exhibits cyclic stability at 550°C, and cyclic softening afterwards at 720°C with Δε/2=0.4% , and of cyclic softening at 720°C with Δε/2=0.7%. After high temperature low cycle fatigue, the γ′ precipitates are cuboidal for all samples. No coarsening of γ′ precipitates was detected at 550°C and at 720°C with Δε/2=0.4%, but small γ′ precipitates get together to be larger precipitates at 720°C with Δε/2=0.7%. EBSD shows that the continuous small angle grain boundaries are produced during the fatigue. The small angle grain boundaries have a significant increase at 720°C, especially that case at Δε/2=0.7%.
29
Binda, Federico, and Shuji Saito. "RELATIVE CYCLES WITH MODULI AND REGULATOR MAPS." Journal of the Institute of Mathematics of Jussieu 18, no. 06 (November 2, 2017): 1233–93. http://dx.doi.org/10.1017/s1474748017000391.
Full textAbstract:
Let $\overline{X}$ be a separated scheme of finite type over a field $k$ and $D$ a non-reduced effective Cartier divisor on it. We attach to the pair $(\overline{X},D)$ a cycle complex with modulus, those homotopy groups – called higher Chow groups with modulus – generalize additive higher Chow groups of Bloch–Esnault, Rülling, Park and Krishna–Levine, and that sheafified on $\overline{X}_{\text{Zar}}$ gives a candidate definition for a relative motivic complex of the pair, that we compute in weight $1$ . When $\overline{X}$ is smooth over $k$ and $D$ is such that $D_{\text{red}}$ is a normal crossing divisor, we construct a fundamental class in the cohomology of relative differentials for a cycle satisfying the modulus condition, refining El Zein’s explicit construction of the fundamental class of a cycle. This is used to define a natural regulator map from the relative motivic complex of $(\overline{X},D)$ to the relative de Rham complex. When $\overline{X}$ is defined over $\mathbb{C}$ , the same method leads to the construction of a regulator map to a relative version of Deligne cohomology, generalizing Bloch’s regulator from higher Chow groups. Finally, when $\overline{X}$ is moreover connected and proper over $\mathbb{C}$ , we use relative Deligne cohomology to define relative intermediate Jacobians with modulus $J_{\overline{X}|D}^{r}$ of the pair $(\overline{X},D)$ . For $r=\dim \overline{X}$ , we show that $J_{\overline{X}|D}^{r}$ is the universal regular quotient of the Chow group of $0$ -cycles with modulus.
30
Jambor, Michal, František Nový, Otakar Bokůvka, Libor Trško, and Monika Oravcová. "Influence of structure sensitising of the AlSi 316Ti austenitic stainless steel on the ultra-high cycle fatigue properties." MATEC Web of Conferences 157 (2018): 05011. http://dx.doi.org/10.1051/matecconf/201815705011.
Full textAbstract:
Austenitic stainless steels are the wide-spread materials, used mainly in the power industry. In that kind of engineering application, structural parts of rotating elements reach during their lifetime very high numbers of loading cycles, exceeding 107 numbers of cycles. With regard to this fact, the data of ultra-high cycle fatigue properties are needed to be used in the qualified design. Increasing demands on the efficiency cause the increase of the operating temperature, and exposition of these materials to the elevated temperatures can cause some important structural changes, which result in the sensitising of the structure. In this study authors present their own experimental results about fatigue properties of AISI 316Ti austenitic stainless steel after sensitising, in the ultra-high cycle region (Nf = 106 ~ Nf = 3×109 cycles). Fatigue tests were carried out using ultrasonic fatigue testing device with frequency f = 20 kHz at the coefficient of cycle asymmetry R = -1, and temperature T = 20±5°C. In the ultra-high cycle region was observed the continuous decrease of the fatigue properties of the AISI 316Ti, and there was recorded the negative effect of the sensitising on the ultra-high cycle fatigue properties of the AISI 316Ti.
31
Dong, Xuan, Weixin Li, Xiaojie Wang, and Yunhong Wang. "Cycle-CNN for Colorization towards Real Monochrome-Color Camera Systems." Proceedings of the AAAI Conference on Artificial Intelligence 34, no. 07 (April 3, 2020): 10721–28. http://dx.doi.org/10.1609/aaai.v34i07.6700.
Full textAbstract:
Colorization in monochrome-color camera systems aims to colorize the gray image IG from the monochrome camera using the color image RC from the color camera as reference. Since monochrome cameras have better imaging quality than color cameras, the colorization can help obtain higher quality color images. Related learning based methods usually simulate the monochrome-color camera systems to generate the synthesized data for training, due to the lack of ground-truth color information of the gray image in the real data. However, the methods that are trained relying on the synthesized data may get poor results when colorizing real data, because the synthesized data may deviate from the real data. We present a new CNN model, named cycle CNN, which can directly use the real data from monochrome-color camera systems for training. In detail, we use the colorization CNN model to do the colorization twice. First, we colorize IG using RC as reference to obtain the first-time colorization result IC. Second, we colorize the de-colored map of RC, i.e. RG, using the first-time colorization result IC as reference to obtain the second-time colorization result R′C. In this way, for the second-time colorization result R′C, we use the original color map RC as ground-truth and introduce the cycle consistency loss to push R′C ≈ RC. Also, for the first-time colorization result IC, we propose a structure similarity loss to encourage the luminance maps between IG and IC to have similar structures. In addition, we introduce a spatial smoothness loss within the colorization CNN model to encourage spatial smoothness of the colorization result. Combining all these losses, we could train the colorization CNN model using the real data in the absence of the ground-truth color information of IG. Experimental results show that we can outperform related methods largely for colorizing real data.
32
Faizin, Rusdi, Raidayani Raidayani, Yoga Nugroho, and Irma Yanti. "Sun-Dried Bilimbi (Averrhoa Bilimbi L) as an Additional Income For Housewives In Ujong Tanoh Darat Village, Meureubo Sub-District, Aceh Barat Regency, Aceh." Budapest International Research in Exact Sciences (BirEx) Journal 2, no. 2 (April 16, 2020): 184–87. http://dx.doi.org/10.33258/birex.v2i2.878.
Full textAbstract:
This study aims to calculate the additional amount of housewife income in Ujong Tanoh Darat Village, Meureubo District, West Aceh Regency as a producer of sun-dried bilimbi. Respondents in this study were ten producers in Ujong Tanoh Darat Village. Data collection techniques by observing and interviewing in detail related to the analysis of sun-dried bilimbi producer income. The data analysis method uses cost analysis, production revenue, production income, and revenue cost ratio (R / C). From the results of data processing in this study, it found that the average income earned by producers was Rp.300,550 per cycle, the average producer income was Rp. 602,000 per cycle and the average production cost incurred by producers is Rp.301,499 per cycle, and the R per C ratio obtained is 1.9, greater than 1 meaning the sun-dried bilimbi producer business in Ujong Tanoh Darat Village, Meureubo District West Aceh is feasible.
33
Coelho, Henrique, Cristina Gonçalves, Claudia Casais, Marisol Guerra, Alexandra Mota, Antonio P. Ribeiro, and Jorge Coutinho. "Rituximab Added to Cyclophosphamide, Vincristine and Prednisolone in Heavily Pretreated Chronic Lymphocytic Leukemia." Blood 106, no. 11 (November 16, 2005): 5023. http://dx.doi.org/10.1182/blood.v106.11.5023.5023.
Full textAbstract:
Abstract Purpose: Although patients with chronic lymphocytic leukemia (CLL) typically respond to available front-line chemotherapy, the response is often temporary, and patients frequently undergo relapse. The authors report the beneficial clinical activity and tolerability of an immunochemotherapeutic regimen consisting of rituximab added to cyclophosphamide, vincristine and prednisolone (R-CVP), in patients with heavily pretreated CLL. Methods: The therapeutic regimen consisted of: cyclophosphamide 750 mg/m2 iv on day one, vincristine 1.4 mg/m2 iv on day one and prednisolone 100 mg po for five consecutive days every 4 weeks, combined with rituximab at a dose of 375 mg/m2 on day 1 of each cycle. Patients were evaluated after three cycles, with responding patients receiving up to eight cycles. No infectious prophylaxis was administered. Results: Five patients have been treated with R-CVP: median age 65 years (range 52–68), advanced Binet stage (four stage C and one stage B) and heavily pretreated (range 1–3 prior therapies). All patients received at least three cycles of R-CVP. Clinical and hematological response was achieved in two patients. Three patients had stable disease. One patient was re-induced once after disease progression. Data from a median follow-up of 112 months (range 52–128 months) showed that three patients remained free of disease progression 8 months after the first cycle of R-CVP (range 2–14 months). The principle treatment complication was pulmonary aspergillosis. Conclusion: These promising results suggest salvage therapy with R-CVP is beneficial in patients with heavily pretreated CLL.
34
Ngom, B. D., N. M. Ndiaye, N. F. Sylla, B. K. Mutuma, N. Manyala, and M. Chaker. "Binary vanadium pentoxide carbon-graphene foam composites derived from dark red hibiscus sabdariffa for advanced asymmetric supercapacitor." Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences 379, no. 2209 (September 13, 2021): 20200347. http://dx.doi.org/10.1098/rsta.2020.0347.
Full textAbstract:
The development of advanced electrode materials derived from biomass for the next generation of energy storage devices, such as supercapacitors with high specific energy and specific power coupled with a good cycle stability, is required to meet the high demand for electric vehicles and portable devices. In this study, sustainable binary vanadium pentoxide carbon-graphene foam composites (V 2 O 5 @C-R 2 HS/GF) were synthesized using a solvothermal method. The X-ray diffraction, Raman and FTIR techniques were used to study the structural properties of the composites (V 2 O 5 @C-R 2 HS/20 mg GF and V 2 O 5 @C-R 2 HS/40 mg GF). The SEM micrographs displayed an accordion-like morphology resulting from the graphene foam-modified V 2 O 5 @C-R 2 HS composite. The V 2 O 5 @C-R 2 HS, V 2 O 5 @C-R 2 HS/20 mg GF and V 2 O 5 @C-R 2 HS/40 mg GF composites were evaluated in a three-electrode configuration using 6 M potassium hydroxide (KOH) as an aqueous electrolyte. Furthermore, a two-electrode device was carried out by fabricating an asymmetric device (V 2 O 5 @C-R 2 HS/GF//AC) where V 2 O 5 @C-R 2 HS/20 mg GF was used as a positive electrode and activated carbon (AC) as a negative electrode at a cell voltage of 1.6 V in 6 M KOH. The V 2 O 5 @C-R 2 HS/GF//AC showed a high specific energy and specific power values of 55 W h kg −1 and 707 W kg −1 , respectively, at a specific current of 1 A g −1 . The asymmetric device presented a good stability test showing 99% capacity retention up to 10 000 cycles and was confirmed by the floating time up to 150 h with specific energy increasing 23.6% after the first 10 h. This article is part of the theme issue ‘Bio-derived and bioinspired sustainable advanced materials for emerging technologies (part 2)’.
35
bin Ismail, Azhar, Li Ang, Kyaw Thu, and Kim Choon Ng. "Low Temperature Waste Heat Driven Refrigeration Cycle." Applied Mechanics and Materials 819 (January 2016): 241–44. http://dx.doi.org/10.4028/www.scientific.net/amm.819.241.
Full textAbstract:
This work explores the utilization of alternative refrigerants to the conventional silica gel + water adsorption pair for the adsorption chiller cycle. Water as the working fluid in the cycle limits the cooling temperatures to above 0°C due to its triple point. The activated carbon Maxsorb III is thus considered as the adsorbent due to its high micro-porous characteristics which lead to higher uptake values. The isotherms of this adsorbent with natural refrigerant Propane, n-butane as well as refrigerants HFC-134a, R507a and R-32 are fitted to the Dubinin-Astakhov equation and the parameters tabulated. With these isotherms, the performances of these pairs with respect to their Specific Cooling Effects (SCE) are compared for assorted cooling temperature, ambient temperature and waste temperature requirements. It was found that the natural refrigerant propane exhibits the most favorable operational conditions when the required cooling temperature is below 0°C. A mathematical model is thus developed to predict the cycle of the propane cycle and is found to show a good fit to the experimental results.
36
Piñol-Roma, S., and G. Dreyfuss. "Cell cycle-regulated phosphorylation of the pre-mRNA-binding (heterogeneous nuclear ribonucleoprotein) C proteins." Molecular and Cellular Biology 13, no. 9 (September 1993): 5762–70. http://dx.doi.org/10.1128/mcb.13.9.5762.
Full textAbstract:
Heterogeneous nuclear ribonucleoprotein (hnRNP) complexes, the structures that contain heterogeneous nuclear RNA and its associated proteins, constitute one of the most abundant components of the eukaryotic nucleus. hnRNPs appear to play important roles in the processing, and possibly also in the transport, of mRNA. hnRNP C proteins (C1, M(r) of 41,000; C2, M(r) of 43,000 [by sodium dodecyl sulfate-polyacrylamide gel electrophoresis]) are among the most abundant pre-mRNA-binding proteins, and they bind tenaciously to sequences relevant to pre-mRNA processing, including the polypyrimidine stretch of introns (when it is uridine rich). C proteins are found in the nucleus during the interphase, but during mitosis they disperse throughout the cell. They have been shown previously to be phosphorylated in vivo, and they can be phosphorylated in vitro by a casein kinase type II. We have identified and partially purified at least two additional C protein kinases. One of these, termed Cs kinase, caused a distinct mobility shift of C proteins on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. These phosphorylated C proteins, the Cs proteins, were the prevalent forms of C proteins during mitosis, and Cs kinase activity was also increased in extracts prepared from mitotic cells. Thus, hnRNP C proteins undergo cell cycle-dependent phosphorylation by a cell cycle-regulated protein kinase. Cs kinase activity appears to be distinct from the well-characterized mitosis-specific histone H1 kinase activity. Several additional hnRNP proteins are also phosphorylated during mitosis and are thus also potential substrates for Cs kinase. These novel phosphorylations may be important in regulating the assembly and disassembly of hnRNP complexes and in the function or cellular localization of RNA-binding proteins.
37
Piñol-Roma, S., and G. Dreyfuss. "Cell cycle-regulated phosphorylation of the pre-mRNA-binding (heterogeneous nuclear ribonucleoprotein) C proteins." Molecular and Cellular Biology 13, no. 9 (September 1993): 5762–70. http://dx.doi.org/10.1128/mcb.13.9.5762-5770.1993.
Full textAbstract:
Heterogeneous nuclear ribonucleoprotein (hnRNP) complexes, the structures that contain heterogeneous nuclear RNA and its associated proteins, constitute one of the most abundant components of the eukaryotic nucleus. hnRNPs appear to play important roles in the processing, and possibly also in the transport, of mRNA. hnRNP C proteins (C1, M(r) of 41,000; C2, M(r) of 43,000 [by sodium dodecyl sulfate-polyacrylamide gel electrophoresis]) are among the most abundant pre-mRNA-binding proteins, and they bind tenaciously to sequences relevant to pre-mRNA processing, including the polypyrimidine stretch of introns (when it is uridine rich). C proteins are found in the nucleus during the interphase, but during mitosis they disperse throughout the cell. They have been shown previously to be phosphorylated in vivo, and they can be phosphorylated in vitro by a casein kinase type II. We have identified and partially purified at least two additional C protein kinases. One of these, termed Cs kinase, caused a distinct mobility shift of C proteins on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. These phosphorylated C proteins, the Cs proteins, were the prevalent forms of C proteins during mitosis, and Cs kinase activity was also increased in extracts prepared from mitotic cells. Thus, hnRNP C proteins undergo cell cycle-dependent phosphorylation by a cell cycle-regulated protein kinase. Cs kinase activity appears to be distinct from the well-characterized mitosis-specific histone H1 kinase activity. Several additional hnRNP proteins are also phosphorylated during mitosis and are thus also potential substrates for Cs kinase. These novel phosphorylations may be important in regulating the assembly and disassembly of hnRNP complexes and in the function or cellular localization of RNA-binding proteins.
38
Jutand, Anny. "Dual role of nucleophiles in palladium-catalyzed Heck, Stille, and Sonogashira reactions." Pure and Applied Chemistry 76, no. 3 (January 1, 2004): 565–76. http://dx.doi.org/10.1351/pac200476030565.
Full textAbstract:
In palladium-catalyzed Heck, Stille, or Sonogashira reactions, the nucleophiles-respectively, alkenes, vinylstannanes, or alkynes-are involved in carbopalladation or transmetallation steps that follow the oxidative addition of an aryl halide or triflate to a Pd0 complex. As soon as the nucleophiles possess a C=C or a C 'triple-bond' C bond capable of coordinating the Pd0 complex active in the oxidative addition, they play a dual role since they interfere in the oxidative addition by a decelerating effect due to a partial coordination of the active Pd0 complex. Indeed, its concentration decreases due to the formation of either unreactive complexes (η2-RCH=CH2)Pd0L2 (R = Ph, CO2Et, L = PPh3 ; R = Bu3Sn, L = AsPh3), (η2-RCH=CH2)Pd0L2(OAc)- (R = Ph, L = PPh3), (η2-R-C 'triple-bond' CH)Pd0L2 (R = Ph, L = PPh3) or more slowly reactive complexes (η2-R-C 'triple-bond' CH)Pd0L2 (R = CO2Et, L = PPh3), (η2-RCH=CH2)Pd0L2 (R= CO2Me, L2 = dppf). Whenever the oxidative addition is faster than the ensuing carbopalladation or transmetallation, the decelerating effect of the nucleophiles in the oxidative addition is in favor of a better efficiency for the catalytic cycle by bringing the rate of the fast oxidative addition closer to that of the slow carbopalladation or transmetallation steps.
39
Dolan, Stan. "The geometric unfolding of recurrence relations." Mathematical Gazette 104, no. 561 (October 8, 2020): 403–11. http://dx.doi.org/10.1017/mag.2020.95.
Full text
40
Rosyida, Isnaini, and Diari Indriati. "Computing total edge irregularity strength of some n-uniform cactus chain graphs and related chain graphs." Indonesian Journal of Combinatorics 4, no. 1 (June 28, 2020): 53. http://dx.doi.org/10.19184/ijc.2020.4.1.6.
Full textAbstract:
<div class="page" title="Page 1"><div class="layoutArea"><div class="column"><p><span>Given graph </span><em>G</em><span>(</span><span><em>V</em>,<em>E</em></span><span>)</span><span>. We use the notion of total </span><em>k</em><span>-labeling which is edge irregular. The notion </span>of total edge irregularity strength (tes) of graph <em>G</em> means the minimum integer <em>k</em> used in the edge irregular total k-labeling of <em>G</em>. A cactus graph <em>G</em> is a connected graph where no edge lies in more than one cycle. A cactus graph consisting of some blocks where each block is cycle <em>C<sub>n</sub></em> with same size <em>n</em> is named an <em>n</em>-uniform cactus graph. If each cycle of the cactus graph has no more than two cut-vertices and each cut-vertex is shared by exactly two cycles, then <em>G</em> is called <em>n</em>-uniform cactus chain graph. In this paper, we determine tes of n-uniform cactus chain graphs <em>C</em>(<em>C<sub>n</sub><sup>r</sup></em>) of length <em>r</em> for some <em>n</em> ≡ 0 mod 3. We also investigate tes of related chain graphs, i.e. tadpole chain graphs <em>T<sub>r</sub></em>(4,<em>n</em>) and <em>T<sub>r</sub></em>(5,<em>n</em>) of length <em>r</em>. Our results are as follows: tes(<em>C</em>(<em>C<sub>n</sub><sup>r</sup></em>)) = ⌈(<em>nr</em> + 2)/3⌉ ; tes(<em>T<sub>r</sub></em>(4,<em>n</em>)) = ⌈((5+<em>n</em>)<em>r</em>+2)/3⌉ ; tes(<em>T<sub>r</sub></em>(5,<em>n</em>)) = ⌈((5+<em>n</em>)<em>r</em>+2)/3⌉.</p></div></div></div>
41
Karlík, Miroslav, Petr Homola, Peter Sláma, Jiří Čapek, and Petr Harcuba. "Influence of homogenization on the microstructure, mechanical properties and texture of the twin-roll cast AA8006 sheet processed by accumulative roll-bonding." MATEC Web of Conferences 326 (2020): 05003. http://dx.doi.org/10.1051/matecconf/202032605003.
Full textAbstract:
Unhomogenized and homogenized AA8006 (Al-Fe-Mn-Si) alloy sheets twin-roll cast to strip 8.5 mm thick, processed by accumulative roll-bonding (ARB) on 2 mm thick sheets up to 6 cycles were studied. The microstructure was characterized by means of scanning and transmission electron microscopy and electron backscattered diffraction (EBSD), mechanical properties were monitored by hardness measurements and tensile tests. The macroscopic texture was determined by X-ray diffraction. The initial texture of the unhomogenized sheet is rotated cubic {001}<110> combined with recrystallization R texture {011}<211>, while the homogenized sheet has a cubic texture {001}<100> with remaining rolling component C {112}<111>. One ARB cycle leads to the formation of low-angle grain boundaries (LAGB) in original coarser grains and to a low angle rotation of the subgrains bounded by LAGB. After the 3rd and 6th ARB cycle unhomogenized and homogenized sheets show a common rolling texture of cold-rolled aluminium. The thermal stability of sheets processed by 6 ARB cycles was tested by isochronal annealing for 30 min up to 450°C. The homogenized sheet starts to recrystallize at 250°C, while the fine grain structure of the unhomogenized sheet is thermally stable up to 400°C.
42
Fan, Peng, and Hualing Chen. "Optimizing the Energy Harvesting Cycle of a Dissipative Dielectric Elastomer Generator for Performance Improvement." Polymers 10, no. 12 (December 4, 2018): 1341. http://dx.doi.org/10.3390/polym10121341.
Full textAbstract:
This paper optimizes the energy harvesting cycle of dissipative dielectric elastomer generators (DEGs) to explore possible approaches for improving the energy harvesting performance. By utilizing the developed theoretical framework, the dissipative performance of the DEG with a constant voltage cycle is analyzed, which shows good agreement with the existing experimental data. On this basis, we design a novel energy harvesting cycle and a corresponding energy harvesting circuit in which a transfer capacitor is utilized to store the charge transferred from the DEG. Then, the energy conversion performance of the DEG with the novel energy harvesting cycle is investigated. The results indicate that both the energy density and conversion efficiency are improved by choosing a high voltage during the discharging process and that as the R-C time constant increases, the enhancement effect of the voltage increases and then approaches to the saturation. In addition, there is an optimal transfer capacitor that can maximize energy density or conversion efficiency, and the optimal transfer capacitor increases with the increase in the R-C time constant. These results and methods are expected to guide the optimal design and assessment of DEGs.
43
DUMORTIER, FREDDY, and HIROSHI KOKUBU. "Chaotic dynamics in ${\mathbb Z}_2$-equivariant unfoldings of codimension three singularities of vector fields in ${\mathbb R}^3$." Ergodic Theory and Dynamical Systems 20, no. 1 (February 2000): 85–107. http://dx.doi.org/10.1017/s0143385700000067.
Full textAbstract:
We study the most generic nilpotent singularity of a vector field in ${\mathbb R}^3$ which is equivariant under reflection with respect to a line, say the $z$-axis. We prove the existence of eight equivalence classes for $C^0$-equivalence, all determined by the 2-jet. We also show that in certain cases, the ${\mathbb Z}_2$-equivariant unfoldings generically contain codimension one heteroclinic cycles which are comparable to the Shil'nikov-type homoclinic cycle in non-equivariant unfoldings. The heteroclinic cycles are accompanied by infinitely many horseshoes and also have a reasonable possibility of generating suspensions of Hénon-like attractors, and even Lorenz-like attractors.
44
Nadler, R. D., J. F. Dahl, and D. C. Collins. "Serum and urinary concentrations of sex hormones and genital swelling during the menstrual cycle of the gibbon." Journal of Endocrinology 136, no. 3 (March 1993): 447–55. http://dx.doi.org/10.1677/joe.0.1360447.
Full textAbstract:
ABSTRACT The relationship between sex hormone concentrations and female genital swelling during the menstrual cycle in the monogamous gibbon was comparable with that of polygamous female primates, such as the chimpanzee, which live in multimale groups and have larger swellings. The data, therefore, support the hypothesis proposed by C. R. Carpenter more than 50 years ago, that the gibbon's genital swelling, like that of other female primates, reflects basic physiological processes associated with progress of the menstrual cycle. Genital swelling increased during the follicular phase with increasing concentrations of oestradiol and oestrone glucuronide, reached maximal swelling in association with the mid-cycle peaks in the oestrogens and LH and began detumescence with the initial increases in progesterone during the luteal phase. The data also suggest that the menstrual cycle of the gibbon is shorter than previously reported, since cycles of 19–22 days exhibited hormone patterns that are consistent with ovulation. The genital swelling of the female gibbon is a useful marker for monitoring progress of the menstrual cycle and the presumptive time of ovulation. Journal of Endocrinology (1993) 136, 447–455
45
Castellino, Alessia, Levy D. Pederson, Kay M. Ristow, Christina Stenzel, Betsy Laplant, Thomas E. Witzig, Thomas M. Habermann, Grzegorz S. Nowakowski, and Luis Porrata. "Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma." Blood 132, Supplement 1 (November 29, 2018): 4139. http://dx.doi.org/10.1182/blood-2018-99-114010.
Full textAbstract:
Abstract Introduction. The peripheral blood absolute lymphocyte (ALC)/monocyte (AMC) ratio (ALC/AMC), as a surrogate of host immunity (i.e. ALC) and tumor microenvironment (i.e. AMC), is a predictive biomarker for clinical outcomes in diffuse large B-cell (DLBCL) patients. An ALC/AMC ratio ≥ 1.1 has been shown to be predictive of better survival both at baseline and during each therapy cycle in patients treated with R-CHOP [Porrata et al, 2014]. Lenalidomide is an immunomodulatory drug, effective in DLBCL patients, with various mechanisms of actions on the tumor microenvironment and the host immune response. In this study we analyze the prognostic value of ALC/AMC ratio in a cohort of newly diagnosed DLBCL patients treated with Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, R2-CHOP) in a phase II trial (MC078E trial, [Nowakowski et al, 2015]). Methods. All patients with de-novo DLBCL enrolled in the phase II trial MC078E and treated at diagnosis with R2-CHOP regimen were included in the analysis. We investigated the ALC/AMC ratio at baseline and each R2-CHOP cycle as predictor of progression-free survival (PFS) and overall survival (OS). The ALC/AMC ratio was obtained by dividing the ALC by the AMC from the automated white blood cell differential obtained from the complete blood cell count on day 0 of each treatment cycle (range from day -3 to day 0 of each course). Patients were then divided in 4 groups on the basis of pattern of ALC/AMC ratio during treatment: group A: patients with ALC/AMC ratio ≥ 1.1 throughout all cycles; group B: patients with ALC/AMC ratio ≥ 1.1 at baseline, but then obtained an ALC/AMC < 1.1 during treatment; group C: patients with ALC/AMC ratio < 1.1 at baseline, but then gained an ALC/AMC ≥ 1.1 during treatment; group D: patients with ALC/AMC ratio < 1.1 throughout all cycles. PFS and OS were analyzed in the different groups. We separately conducted the same analysis in a matched control cohort of 94 DLBCL patients from the Mayo Clinic Lymphoma Database treated with standard R-CHOP. Results. A total of 63 patients with de-novo DLBCL treated with R2CHOP regimen at diagnosis were included in the analysis. Clinical characteristics were: median age 67 years (22-87), male sex 61.9%, III-IV advance stage 87.3%, elevated LDH serum levels 66.7%, intermediate-high/high International Prognostic index (IPI) score in 54% cases. No differences in 3y-PFS and 3y-OS in patients with ALC/AMC ratio ≥ 1.1 vs ALC/AMC < 1.1 at baseline and at each R2-CHOP course have been observed. In a landmark analysis from day 0 of the last cycle, 3y-PFS in group A vs B vs C vs D was: 71.4% vs 67.1% vs 66.7% vs 85.7%, respectively (p 0.80); 3y-OS in group A vs B vs C vs D was: 85.7% vs 86.5% vs 66.7% vs 100%, respectively (p 0.74). No differences in both 3y-PFS and 3y-OS were observed comparing group A vs B, in group C vs D, and in group A vs D. Unlike what was observed in the R-CHOP treated DLBCL patients, in a univariate analysis ALC/AMC < 1.1 during all cycles of R2CHOP was not a predictor for inferior outcomes (Figure 1.a). In the matched cohort of patients treated with standard R-CHOP, ALC/AMC < 1.1 at baseline and at each course demonstrated to be predictive of worse outcome (p <0.01),survival was significantly different in the 4 groups identified according to ALC/AMC ratio during treatment and ALC/AMC < 1.1 maintained during all cycles of R2CHOP was predictive of worse PFS and OS (Figure 1.b). Conclusions. Lenalidomide in combination with standard R-CHOP (R2-CHOP), in previously untreated DLBCL patients, appears to overcome the negative prognostic value of ALC/AMC ratio observed in patients treated with R-CHOP alone. This could reflect the additional effect of lenalidomide to standard therapy on tumor microenvironment and on host immunity response. Figure 1: Landmark Analysis for Progression Free Survival and Overall Survival by ALC/AMC groups within R2CHOP (1.A) and R-CHOP (1.B). Group A: ALC/AMC >=1.1 for all cycles; Group B: ALC/AMC >=1.1 at baseline and obtained <1.1 during treatment; Group C: ALC/AMC <1.1 at baseline and obtained >=1.1 during treatment; Group D: ALC/AMC <1.1 for all cycles. Disclosures Witzig: Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.
46
Piotrowski, Anna, Vinay Puduvalli, Patrick Wen, Jian Campian, Howard Colman, Michael Pearlman, Nicholas Butowski, et al. "ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE." Neuro-Oncology 21, Supplement_6 (November 2019): vi21—vi22. http://dx.doi.org/10.1093/neuonc/noz175.081.
Full textAbstract:
Abstract Pamiparib, an investigational, selective PARP1/2 inhibitor that has demonstrated potent PARP trapping and ability to cross the blood-brain barrier, showed synergistic cytotoxicity with TMZ preclinically. We report updated safety and antitumor effects from a phase 1b/2 study of pamiparib + RT and/or TMZ in patients with newly diagnosed or R/R GBM (SNO 2018, ACTR-30). The dose-escalation/expansion study has 3 arms: Arm A, pamiparib (2, 4, or 6 weeks) + RT in newly diagnosed GBM patients with unmethylated MGMT promoter (unmethylated-GBM); Arm B, pamiparib (6 weeks) + RT and increasing TMZ dosed in weeks 1 and 5 of RT in newly diagnosed, unmethylated-GBM patients; and Arm C, pamiparib + increasing TMZ doses in methylated/unmethylated R/R-GBM patients. Arm A and B patients receive maintenance treatment post-RT rest period at the Arm C expansion dose/schedule. As of 10 April 2019, accrual was completed for Arms A and C dose-escalation (A: n=20; C: n=17) and continues in the dose expansion (A: n=28/40; C: n=28/30); accrual was completed in dose escalation for B (n=9). Recommended phase 2 doses were established for Arms A (pamiparib 60 mg BID×6 weeks + 6–7 weeks RT) and C (pamiparib 60 mg BID d1–28 + TMZ 60 mg d1–7/28-d cycle). One dose-limiting toxicity (grade 3 febrile neutropenia) was reported in Arm B. Treatment-related adverse events (≥10%) were (overall/grade 3 [no grade 4/5]): Arm A, nausea (23%/2%); B, decreased WBC count (11%/11%); C (none). Of patients with tumor assessment post-RT: Arm A (n=17), 1 had cPR, 1 uPR, and 9 SD (disease control rate, 64.7% [95% CI, 38.3–85.8]); C (n=26), 1 had cPR (sustained 12 cycles), 1 uPR, and 5 SD (objective response rate, 7.7% [95% CI, 0.9–25.1]). Pamiparib 60 mg BID + RT/TMZ was generally well tolerated in patients with newly diagnosed or R/R GBM. Clinical trial ID: NCT03150862
47
Vergote, Ignace, Florian Heitz, Paul Buderath, Matthew A. Powell, Jalid Sehouli, Christine M. Lee, Anne L. Hamilton, et al. "A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 5537. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5537.
Full textAbstract:
5537 Background: p38 mitogen-activated protein kinase (MAPK) regulates cytokine production in the tumor microenvironment and enables therapeutic resistance of cancer cells. Ralimetinib (R) is a selective small-molecule inhibitor of p38α and p38β MAPKs. Methods: Main inclusion criteria: ≥18 y; recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal, cancer after first-line treatment. Phase (Ph)1b was to determine the recommended Ph2 dose (RP2D) of R administered 12-hourly (Q12H) on Days 1-10 (21-day cycle [Q21D]) in combination with gemcitabine (G: 1000 mg/m2 on Days 3 and 10) and carboplatin (C: AUC 4 on Day 3) for 6 cycles. In Ph2, patients (pts) were randomized double-blind, 1:1 to RP2D R+GC or placebo (P)+GC, for 6 cycles, followed by R 300 mg Q12H or P on Days 1-14, Q28D until disease progression. The stratified log-rank test compared progression-free survival (PFS; primary endpoint) between treatment groups in Ph2, at a 1-sided α level of 0.2. ClinicalTrials.gov, NCT01663857. Results: 118 pts received ≥1 dose of R or P (safety population); 8 in Ph1b and 110 in Ph2 (R+GC N = 58; P+GC N = 52). The RP2D for R in combination with GC was 200 mg Q12H. The study met its primary objective (median PFS: R+GC 10.3 mo vs P+GC 7.9 mo; HR = 0.773, 2-sided p = 0.246). The secondary objectives of median overall survival (R+GC 29.2 mo vs P+GC 25.1 mo; HR = 0.827, p = 0.469) or overall response rate (R+GC 46.6% vs P+GC 46.2%; p = 0.967) were not statistically significant, and 32.4% vs 25.0% of pts had normalized CA125 at the end of cycle 6. Most pts (safety population) experienced ≥1 Grade 3/4 treatment-emergent adverse event (TEAE: R+GC 63/66 [95.5%]; P+GC 48/52 [92.3%]). Decreased neutrophil count (60.6% vs 76.9%), platelet count (43.9% vs 38.5%), and white blood cell count, (30.3% vs 26.9%), anemia (22.7% vs 25.0%), and increased alanine aminotransferase (ALT) (19.7% vs 3.8%) were the Grade 3/4 TEAEs in ≥10% of pts in the R+GC and P+GC arms, respectively. Conclusions: Addition of ralimetinib to GC resulted in modest improvements in PFS. Grade 3/4 elevated ALT was more common in the ralimetinib arm. Clinical trial information: NCT01663857.
48
Plumtree, Alan, and M. M. Mirzazadeh. "Fully Reversed Uniaxial Tension-Compression High Cycle Fatigue Behaviour of Shot-Peened Steels." Key Engineering Materials 488-489 (September 2011): 21–24. http://dx.doi.org/10.4028/www.scientific.net/kem.488-489.21.
Full textAbstract:
The effect of shot-peening on the uniaxial fatigue behaviour of four engineering steels, heat treated to a similar final hardness was investigated. Forged 0.39%C and 0.72%C steels, a quenched and tempered 0.51%C steel and a 0.50%C powder forged (PF) steel were fatigue tested under fully reversed (R=-1) push-pull loading conditions. Following long life (107) cycling, shot-peening had little effect on the fatigue limit of the 0.39%C and 0.72%C steels whereas the fatigue limit of the PF steel increased 10.4%. Conversely, the fatigue limit of the quenched and tempered steel decreased 12.0% after shot-peening. The results showed that the beneficial effects of shot-peening, such as compressive residual stresses and work hardening, balanced the effects of surface roughness since crack initiation tended to occur below the surface. Microhardness profiles showed that the greatest amount of cyclic softening in the shot-peened regions occurred in the hot rolled steels. Softening was accompanied by a decrease in the depth of surface hardness.
49
Tarantino, G., M. R. Sacco, A. Ceriello, and L. Morelli. "Three r-IFN-beta regimens for retreatment of PTS suffering from chronic C hepatitis, non responder to a previous cycle of r-IFN-alpha." Gastroenterology 114 (April 1998): A1352—A1353. http://dx.doi.org/10.1016/s0016-5085(98)85490-5.
Full text
50
Segers, Patrick, Nikos Stergiopulos, and Nico Westerhof. "Relation of effective arterial elastance to arterial system properties." American Journal of Physiology-Heart and Circulatory Physiology 282, no. 3 (March 1, 2002): H1041—H1046. http://dx.doi.org/10.1152/ajpheart.00764.2001.
Full textAbstract:
Effective arterial elastance ( E a), defined as the ratio of left ventricular (LV) end-systolic pressure and stroke volume, lumps the steady and pulsatile components of the arterial load in a concise way. Combined with E max, the slope of the LV end-systolic pressure-volume relation, E a/ E max has been used to assess heart-arterial coupling. A mathematical heart-arterial interaction model was used to study the effects of changes in peripheral resistance ( R; 0.6–1.8 mmHg · ml−1 · s) and total arterial compliance (C; 0.5–2.0 ml/mmHg) covering the human pathophysiological range. E a, E a/ E max, LV stroke work, and hydraulic power were calculated for all conditions. Multiple-linear regression analysis revealed a linear relation between E a, R/ T (where T is cycle length), and 1/C: E a= −0.13 + 1.02 R/ T + 0.31/C, indicating that R/ T contributes about three times more to E a than arterial stiffness (1/C). It is demonstrated that different pathophysiological combinations of R and C may lead to the same E a and E a/ E max but can result in differences of 10% in stroke work and 50% in maximal power.